Per Order of the State Administration of Market Regulation No. 44 entitled Measures for the Administration of Lists of Serious Illegal and Dishonest Acts Subject to Market Regulation (市场监督管理严重违法失信名单管理办法), effective September 1, 2021, China’s State Administration for Market Regulation (SAMR) will establish a list of untrustworthy entities that have intentionally infringed intellectual property , misappropriated trade secrets, committed unfair competition (frequently a cause of action in trademark infringement cases), filed abnormal (irregular) patent applications, maliciously submitted trademark applications (e.g., for …
Category: Patents
China’s Supreme People’s Court Rules Utility Model Patent Unenforceable if Corresponding Invention Patent Application Fails to Grants
In a decision released by the Intellectual Tribunal of China’s Supreme People’s Court (SPC) on July 23, 2021, the SPC explained that a granted utility model patent may be unenforceable when a corresponding invention patent application was rejected during substantive examination. The plaintiff had filed both utility model and invention patent applications on the same day for the same invention. While the utility model granted, the invention patent application was rejected in substantive examination for lacking novelty and inventiveness.
China’s New Patent Linkage System: A Guide for Foreign Chinese Patent Holders
This article originally appeared in IP Watchdog here. In compliance with the Phase One Trade Agreement, China has implemented a patent linkage system in their amended patent law, which became effective June 1, 2021 (Article 76 of the Patent Law of the People’s Republic of China (2020)). The Chinese patent linkage system prevents marketing approval of generic drugs until after the expiration of patents covering the drugs or uses. Specifically, the Center for Drug Evaluation (CDE) of the National Medical Products Administration …
First Generic Declarations Published on China’s New Patent Linkage System
As of July 13, 2021, four generic declarations have been filed so far on China’s new patent linkage registration system. In compliance with the Phase One Trade Agreement, China implemented a patent linkage system in their amended patent law effective June 1, 2021. The Chinese patent linkage system prevents marketing approval of generic drugs until after the expiration of patents covering the drugs or uses. The 4 declarations are all from Chinese companies for drugs from Western companies including GlaxoSmithKline …